Results 211 to 220 of about 2,654,129 (357)

Systematic review of systematic reviews

open access: yes
A systematic review of systematic reviews of policy measures and interventions designed to prevent overweight and obesity among children and adolescents will be provided.
openaire   +1 more source

Impact of Centralizing Care for Genitourinary Malignancies to High-volume Providers: A Systematic Review [PDF]

open access: green, 2018
Stephen B. Williams   +9 more
openalex   +1 more source

β‐TrCP overexpression enhances cisplatin sensitivity by depleting BRCA1

open access: yesMolecular Oncology, EarlyView.
Low levels of β‐TrCP (Panel A) allow the accumulation of BRCA1 and CtIP, which facilitate the repair of cisplatin‐induced DNA damage via homologous recombination (HR) and promote tumor cell survival. In contrast, high β‐TrCP expression (Panel B) leads to BRCA1 and CtIP degradation, impairing HR repair, resulting in persistent DNA damage and apoptosis ...
Rocío Jiménez‐Guerrero   +8 more
wiley   +1 more source

N-of-1 Randomized Intervention Trials in Health Psychology: A Systematic Review and Methodology Critique [PDF]

open access: bronze, 2018
Jonathan A. Shaffer   +4 more
openalex   +1 more source

Nicotinamide N‐methyltransferase promotes drug resistance in lung cancer, as revealed by nascent proteomic profiling

open access: yesMolecular Oncology, EarlyView.
AZD9291 has shown promise in targeted cancer therapy but is limited by resistance. In this study, we employed metabolic labeling and LC–MS/MS to profile time‐resolved nascent protein perturbations, allowing dynamic tracking of drug‐responsive proteins. We demonstrated that increased NNMT expression is associated with drug resistance, highlighting NNMT ...
Zhanwu Hou   +5 more
wiley   +1 more source

Automated tools in systematic reviews: Current trends. [PDF]

open access: yesIndian J Anaesth
Maurya I, Lohiya A, Maurya RG, Garg R.
europepmc   +1 more source

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

open access: yesMolecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham   +21 more
wiley   +1 more source

Enhancing the quality of systematic reviews and meta-analyses. [PDF]

open access: yesBJPsych Open
Strawbridge R   +5 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy